Over-the-counter Heartburn Meds Could Worsen Cancer Treatment

Highlights

• Medications for heartburn and gastrointestinal bleeding reduce the effect of chemotherapy in gastric cancer patients.
• Proton pump inhibitors decreased the disease control by //11% and reduced overall survival by 2 months.
• Nexium, Prevacid and Protonix are some PPIs, very popular for their efficacy and their use as over-the-counter drugs.
Proton pump inhibitors (PPIs), which are very common medications for heartburn and gastrointestinal bleeding, decrease effects of capecitabine, a type of chemotherapy usually prescribed to gastric cancer patients.
The study by Department of Oncology's Michael Sawyer, Michael Chu and their team included more than 500 patients. The results show that PPIs affected progression-free survival by more than a month; the overall survival in cancer patients was reduced by more than two months, and the disease control rate decreased by 11 percent.


Stomach Cancer | Gastric Cancer
Stomach (gastric) cancer develops from the stomach lining. It is the third most common cause for cancer related deaths.
‘Proton pump inhibitors, which are very common medications for heartburn and gastrointestinal bleeding, decrease effects of capecitabine, a type of chemotherapy usually prescribed to gastric cancer patients.’

Tweet it Now
Sawyer's team has followed up with another study in early stage colorectal cancer and discovered that those who took PPIs and capecitabine were also at risk for decreased cancer treatment efficacy. In that study, patients who took PPIs while on capecitabine had a decreased chance of being cured of their colorectal cancer.

Sawyer explains the risk of this interaction is high as some cancer patients may not even have these medications prescribed by a physician, but could obtain them easily over-the-counter at a pharmacy and accidentally alter their chemotherapy treatment without knowing it.

He said, "This could be a very common and underappreciated side effect. One study estimated that at 20 per cent of cancer patients in general take proton pump inhibitors."


Colorectal Cancer - Types, Causes, Risk Factors, Symptoms, Diagnosis, Treatment, Prognosis & Prevention
Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancer is the third most common cancer in men.
The explanation for the negative outcome may be in gastric pH levels. Previous studies had been done on the interaction of this type of chemo with the antacid medication Maalox, without obtaining any alarming results; but unlike Maalox, PPI's are able to raise pH to a point where they could affect disintegration of capecitabine tablets.

"Given that PPIs are much more potent and can essentially abolish gastric acidity there may be a significant interaction between capecitabine and PPIs," says Sawyer.


Advertisement
Fifteen Most Common Chemotherapy Side Effects and Ways to Manage Them
Chemotherapy side effects depend on the chemotherapy treatment as there are varied types of chemotherapy medications. Traditional chemotherapy drugs kill growing cancer cells.
This discovery may lead to change the usual procedures for prescription of PPIs. Some cancer patients cannot discontinue these medications in order to treat bleedings or other gastric conditions that must be kept under control.

"In that case, there are alternatives for oncologists or family doctors that become aware of this risk," says Sawyer. "Physicians should use caution in prescribing PPIs to patients on capecitabine and, if they must use PPIs due to gastrointestinal bleeding issues, maybe they should consider using other types of chemotherapy that don't present this interaction."


Advertisement
Colo-rectal Cancer - Management
Treatment for Colorectal Cancers may involve surgery,chemotherapy, radiation therapy or biological therapy. Some people require a combination of treatments.
Reference

1. Micheal P. Chu, Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial, JAMA Oncology (2016) , http://dx.doi.org/10.1001/jamaoncol.2016.3358 .


Source-Medindia